BRCA1 and ovarian cancer: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), has been approved as the first ‘personalized therapy’ for advanced BRCA1/2 mutated ovarian cancer.4 However, unlike ovarian cancers with nearly half of the cases bearing deficiency in homologous recombination (HR),5 majority of endometrial cancers harbor intact HR pathway, which thus limits the therapeutic utility of PARP inhibitors in this disease.